Distribution and prognostic value of histopathologic data and immunohistochemical markers in gastrointestinal stromal tumours (GISTs): An analysis of the EORTC phase III trial of treatment of metastatic GISTs with imatinib mesylate

European Journal of Cancer

Volumn 44, Issue 13, 2008, Pages 1855-1860

  Sciot, Raf ^a   Debiec Rychter, Maria ^a   Daugaard, Soren ^b   Fisher, Cyril ^c   Collin, Francoise ^d   Glabbeke, Martine van ^e   Verweij, Jaap ^f   Blay, Jean Yves ^g   Hogendoorn, Pancras C W ^h  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b University of Copenhagen   (Denmark)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d Georges Francois Leclerc Cancer Center   (France)

^e EORTC DATA CENTER   (Belgium)

^f ERASMUS MEDICAL CENTER   (Netherlands)

^g EDOUARD HERRIOT HOSPITAL   (France)

^h LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Clinical trials; Gastrointestinal stromal tumour; Immunohistochemistry; Mutational analysis; Pathology; Prognoses; Soft tissue tumours

Indexed keywords

BIOLOGICAL MARKER; IMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; STEM CELL FACTOR RECEPTOR;

ADULT; ADVANCED CANCER; ANTIGEN EXPRESSION; ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; GENE DELETION; GENE MUTATION; GENOTYPE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EXONS; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MALE; MUTATION; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA;

EID: 49549113809     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.06.003     Document Type: Article

References (30)

1. Graadt van Roggen J.F., van Velthuysen M.L., and Hogendoorn P.C. The histopathological differential diagnosis of gastrointestinal stromal tumours. J Clin Pathol 54 (2001) 96-102
2. Goettsch W.G., Bos S.D., Breekveldt-Postma N., et al. Incidence of gastrointestinal Stromal tumours is underestimated: results of a nation-wide study. Eur J Cancer 41 (2005) 2868-2872
3. Nilsson B., Bumming P., Meis-Kindblom J.M., et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era - a population-based study in western Sweden. Cancer 103 (2005) 821-829
4. Blay J.Y., Bonvalot S., Casali P., et al. Consensus meeting for the management of gastrointestinal Stromal tumors. Report of the GIST GIST consensus conference of 20-21 March 2004, under the auspices of European Society for Medical Oncology. Ann Oncol 16 (2005) 566-578
5. Corless C.L., Fletcher J.A., and Heinrich M.C. Biology of gastrointestinal stromal tumors. J Clin Oncol 18 (2004) 3813-3825
6. Pauwels P., Debiec-Rychter M., Stul M., et al. Changing phenotype of gastrointestinal stromal tumours under imatinib mesylate treatment: a potential diagnostic pitfall. Histopathology 47 (2005) 41-47
7. Miettinen M., and Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 130 (2006) 1466-1478
8. Wasag B., Debiec-Rychter M., Pauwels P., et al. Differential expression of KIT/PDGFRA mutant isoforms in epithelioid and mixed variants of gastrointestinal stromal tumors depend predominantly on the tumor site. Mod Pathol 17 (2004) 889-894
9. Wardelmann E., Hrychyk A., Merkelbach-Bruse S., et al. Association of platelet-derived growth factor receptor alpha mutations with gastric primary site and epithelioid or mixed cell morphology in gastrointestinal stromal tumors. J Mol Diagn 6 (2004) 197-204
10. Agaram N.P., Baren A., Arkun K., et al. Comparative ultrastructural analysis and KIT/PDGFRA genotype in 125 gastrointestinal stromal tumors. Ultrastruct Pathol 30 (2006) 443-452
11. Verweij J., Casali P.G., Zalcberg J., et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364 (2004) 1127-1134
12. Debiec-Rychter M., Sciot R., Le Cesne A., et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumors. Eur J Cancer 42 (2006) 1093-1103
13. Van Glabbeke M., Verweij J., Casali P.G., et al. Initial and late resistance to imatinib (IM) in advanced gastro-intestinal stromal tumours (GIST) are predicted by different prognostic factors: an EORTC-ISG-AGITG study. J Clin Oncol 23 (2005) 5795-5804
14. Buchdunger E., Cioffi C.L., Law N., et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295 (2000) 139-145
15. Van Oosterom A.T., Judson I., Verweij J., et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358 (2001) 1421-1423
16. Demetri G.D., von Mehren M., Blanke C.D., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumours. New Engl J Med 347 (2002) 472-480
17. Heinrich M.C., Corless C.L., Demetri G.D., et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumour. J Clin Oncol 21 (2003) 4342-4349
18. Debiec-Rychter M., Dumez H., Judson I., et al. Use of KIT/PDGFRA mutation analysis in predicting clinical response to imatinib in advanced gastrointestinal stromal tumors in phase I and II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 40 (2004) 689-695
19. Miettinen M., Sobin L.H., and Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 29 (2005) 52-68
20. Miettinen M., Makhlouf H., Sobin L.H., et al. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol 30 (2006) 477-489
21. Vanderwinden J.M., Rumessen J.J., De Laet M.H., et al. CD34 immunoreactivity and interstitial cells of Cajal in the human and mouse gastrointestinal tract. Cell Tissue Res 302 (2000) 45-53
22. Corless C.L., Schroeder A., Griffith D., et al. PDGFRA mutations in gastrointestinal Stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 23 (2005) 1-8
23. Vu H.A., Xinh P.T., Kikushima M., et al. A recurrent duodenal gastrointestinal stromal tumor with a frameshift mutation resulting in a stop codon in KIT exon 13. Genes Chromos Cancer 42 (2005) 179-183
24. Martin J., Martin J., Poveda A., et al. Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS). J Clin Oncol 23 (2005) 6190-6198
25. Wardelmann E., Losen I., Hans V., et al. Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behaviour of gastrointestinal stromal tumors. Int J Cancer 106 (2003) 887-895
26. Emile J., Theou N., Tabone S., et al. Clinicopathologic, phenotypic, and genotypic characteristics of gastrointestinal mesenchymal tumors. Clin Gastroenterol Hepatol 2 (2004) 597-605
27. Andersson J., Bu{combining double acute accent}mming P., Meis-Kindblom J.M., et al. Gastrointestinal Stromal tumors with KIT exon 11 deletions are associated with poor prognosis. Gastroenterology 130 (2006) 1573-1581
28. Antonescu C.R., Sommer G., Sarran L., et al. Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal Stromal tumors. Clin Cancer Res 9 (2003) 3329-3337
29. Lasota J., Dansonka-Mieszkowska A., Stachura T., et al. Gastrointestinal stromal tumors with internal tandem duplications in 3′ end of KIT juxtamembrane domain occur predominantly in stomach and generally seem to have a favorable course. Mod Pathol 16 (2003) 1257-1264
30. Lasota J., Dansonka-Mieszkowska A., Sobin L.H., et al. A great majority of GISTs with PDGFRA mutations represent gastric tumor of low or no malignant potential. Lab Invest 84 (2004) 874-883